Technical analysis of CNS Pharmaceuticals, Inc. (CNSP): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Price Performance
| 1 month | -6.14% |
| 3 months | +17.02% |
| Year-to-date | +4.76% |
| 1 year | -37.00% |
| 3 years | -99.99% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $10.59 |
| 52-week Low | $1.90 |
| Avg Volume (90d) | 31K |
Technical Indicators
| SMA 50 | $5.48 |
| SMA 200 | $4.80 |
| 30-day Volatility (annualised) | 64.5% |
| Price vs SMA 50 | +0.4% |
| Price vs SMA 200 | +14.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $7.70 | |
| 2025-11 | $6.94 | -9.9% |
| 2025-12 | $5.25 | -24.4% |
| 2026-01 | $5.58 | +6.3% |
| 2026-02 | $3.11 | -44.3% |
| 2026-03 | $2.39 | -23.2% |
| 2026-04 | $2.27 | -5.0% |
| 2026-05 | $5.44 | +139.6% |
| 2026-06 | $4.78 | -12.1% |
| 2026-07 | $5.82 | +21.8% |
| 2026-08 | $5.98 | +2.7% |
| 2026-09 | $5.50 | -8.0% |
Price
| Price | $5.50 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.01 |
| EV / EBITDA | 0.70 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.86 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -21.50 |